EurekAlert!6d
FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumors, backed by Dana-Farber research
The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...